Plain-English translation of NCT04500665 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that reduces inflammation in the body, can help protect the heart and slow kidney disease progression in people with chronic kidney disease. Researchers want to understand if this medication is both safe and effective for patients whose kidneys aren't working as well as they should. The study will compare the medication to a placebo (a pill with no active ingredient) to see what difference, if any, it makes.
People with chronic kidney disease often develop heart problems as a complication, partly because of inflammation in the body. This medication has anti-inflammatory properties, and researchers believe it might help prevent or slow down these heart complications—but they need to test whether this actually works in kidney disease patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the daily medication or a placebo pill once a day. You'll attend study visits where your kidney function, heart health, and overall well-being will be monitored through blood tests and possibly heart imaging. The study is small (recruiting about 20 people total) and is designed to gather safety information and early evidence about whether this medication works for people with your condition.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Brigham and Women's Hospital
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Enrollment target
~20 participants
Started
November 2021
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
21 Years – 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Leo F Buckley, PharmD MPH
Brigham and Women's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.